The prognostic impact of the lymphocyte-to-C-reactive protein ratio in patients with unresectable or recurrent advanced gastric cancer treated with first- and second-line treatment.

Autor: Matsunaga, Tomoyuki, Saito, Hiroaki, Fukumoto, Yoji, Kuroda, Hirohiko, Taniguchi, Kenjiro, Takahashi, Sadamu, Osaki, Tomohiro, Iwamoto, Akemi, Fukuda, Kenji, Shimizu, Shota, Shishido, Yuji, Miyatani, Kozo, Fujiwara, Yoshiyuki
Předmět:
Zdroj: Surgery Today; Aug2023, Vol. 53 Issue 8, p940-948, 9p
Abstrakt: Purpose: The goal of this study was to determine which markers are the most useful as first- and second-line pre-treatment markers in patients with unresectable or recurrent gastric cancer (URGC). Methods: This study included 101 URGC patients who were treated with first- and second-line chemotherapy. Several prognostic scores based on nutrition and inflammation were analyzed using a receiver operating characteristic (ROC) analysis to determine the most useful prognostic marker. Results: The lymphocyte-to-C-reactive protein ratio (LCR) had the highest area under the curve for both first- and second-line chemotherapy, according to an ROC analysis. An ROC analysis was used to determine the optimal LCR cut-off for the median survival time before first- and second-line chemotherapy, and patients were divided into high- and low-LCR groups. Patients with a high LCR had a significantly longer survival than those with a low LCR before first- and second-line chemotherapy (p = 0.004, p < 0.001, respectively). A low LCR before both first- and second-line chemotherapy was an independent poor prognostic factor in a multivariate analysis. Conclusions: URGC patients with a low LCR before both first- and second-line chemotherapy had a significantly worse prognosis than those with a high LCR in this study. Nutritional intervention during chemotherapy induction may lead to a better prognosis. [ABSTRACT FROM AUTHOR]
Databáze: Complementary Index
Externí odkaz: